Quantitative results corresponding to the work "Engineering a Squamous Cell Carcinoma Platform Based on an Approved ATMP to Enable Precision Therapeutics and Oncology Drug Discovery"

This dataset corresponds to the quantification results carried out for skin cancer platforms developed by tissue engineering and control platforms analyzed in the manuscript entitled "Engineering a Squamous Cell Carcinoma Platform Based on an Approved ATMP to Enable Precision Therapeutics and Oncology Drug Discovery". Bioengineered models can be used to better understand complex biological processes such as cancer development but also as a drug testing platform in order to reduce the use of animals in research as well as they do not fully recreate human conditions. For this reason, our study aimed to generate a biomimetic three-dimensional squamous cell carcinoma (SCC) model by bioengineering the clinical approved used skin substitute (UGRSKIN). By evaluating its biological fidelity, we established a robust tool for personalized medicine research and oncology research. Firstly, the morphological and phenotypical analysis performed by histological and histochemical staining techniques showed that our model recreates disease-like histopathological features related to tumor development processes. Additionally, gene assessment confirmed the results previously observed as well as demonstrated the use of our model (UGRSKIN-CM) as a platform for understanding genetic alterations responsible for tumorigenesis. Finally, the model was also subjected to pharmacological validation by using a tyrosine kinase inhibitor (Gefitinib). The results confirm that our model does not only recreate the histoarchitecture but also the biological response against an anti-tumor drug. Considering the results obtained and the potential to create unique, patient-specific and customizable platforms by incorporating autologous cells make UGRSKIN-CM an ideal tool in the field of personalized medicine. The original data obtained for the quantitative analyses of each component are shown in this dataset.本数据集对应于发表于题为《基于获批先进治疗药物产品（Advanced Therapy Medicinal Product, ATMP）构建鳞状细胞癌（Squamous Cell Carcinoma, SCC）平台以实现精准治疗与肿瘤药物研发》的手稿中所分析的组织工程皮肤癌平台及对照平台的定量检测结果。 生物工程模型可用于深入解析肿瘤发生等复杂生物学过程，同时可作为药物测试平台以减少研究中动物的使用，但其无法完全复刻人类机体的生理状态。 基于此，本研究旨在通过对临床获批使用的皮肤替代物UGRSKIN进行生物工程改造，构建仿生三维鳞状细胞癌模型。通过评估该模型的生物学保真度，我们构建了一款可用于个性化医学与肿瘤学研究的可靠工具。 首先，通过组织学与组织化学染色技术开展的形态学及表型分析显示，本模型可复刻与肿瘤发生进程相关的疾病样组织病理学特征。此外，基因检测验证了前述观察结果，同时证实了本模型（UGRSKIN-CM）可作为解析肿瘤发生相关遗传改变的研究平台。 最后，本模型还通过酪氨酸激酶抑制剂吉非替尼（Gefitinib）开展了药理学验证。实验结果证实，本模型不仅可复刻肿瘤组织的组织架构，还能模拟机体对抗肿瘤药物的生物学应答。 结合本研究所得结果，以及通过引入自体细胞构建个性化、专属化定制平台的潜力，UGRSKIN-CM成为个性化医学领域的理想研究工具。本数据集收录了针对各组分开展定量分析所获得的原始实验数据。